A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
U.S. Approves Over $6.5 Billion in Military Sales to Israel Across Three Defense Contracts
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Syria-Kurdish Ceasefire Marks Historic Step Toward National Unity
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 



